Clinical trials: Calcitonin Gene-related Peptide Receptor
Trigeminal Neuropathy
Erenumab-aooe for the Management of Trigeminal Neuropathic Pain.
This study is a single center, placebo-controlled, double blind, randomized, phase II pilot to evaluate the efficacy of erenumab-aooe in the management of trigeminal neuropathic pain comparing erenumab-aooe vs Placebo.
- Trial name
- NCT05142228
- Testing
- Erenumab-Aooe
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Maryland, Baltimore
Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (OPSCC)
Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell Carcinoma
This study will evaluate whether adding rimegepant to standard neoadjuvant chemoimmunotherapy can improve treatment response in patients with primary or recurrent oral or oropharyngeal squamous cell carcinoma who are planned to…
- Trial name
- NCT07812467
- Testing
- Rimegepant, Tislelizumab, Nab-paclitaxel
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Shanghai Zhongshan Hospital
Episodic Migraine
A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies
The purpose of this study is to determine if AMG 334 is effective in treating migraines in patients who have failed other preventive migraine treatments.
- Trial name
- NCT03096834
- Testing
- AMG334 (70 mg) Pre-Filled Syringe (PFS)
- Where
- 59 sites in Australia, Austria and 14 more
- Volunteers
- 246 people
- Sponsor
- Novartis Pharmaceuticals
Migraine
Efficacy of Rimegepant 75 mg for the Acute Treatment of Migraine: a Bayesian Individual Participant Data Meta-analysis Standardized to Defined Target Populations
This non-interventional study will evaluate the efficacy of rimegepant 75 mg compared with placebo for the acute treatment of moderate or severe migraine attacks using individual participant data (IPD) from six completed…
- Trial name
- NCT07906262
- Testing
- Rimegepant
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
Thyroid Cancer, Medullary, Neuroendocrine Tumor of the Lung Grade 1 and 2
177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer.
The purpose of this study is to determine the use of 177Lu-PP-F11N for imaging and therapy of patients with advanced medullary thyroid carcinoma (MTC). 177Lu-PP-F11N is a gastrin analogon, binding to cholecystokinin-2 receptors.
- Conditions
- Thyroid Cancer, Medullary, Neuroendocrine Tumor of the Lung Grade 1 and 2, Neuroendocrine Tumor of the Thymus Grade 1 and 2, Neuroendocrine Tumor GEP Grade 1-3
- Trial name
- Lumed (NCT02088645)
- Testing
- 177Lu-PP-F11N
- Where
- Switzerland
- Volunteers
- 24 people
- Sponsor
- University Hospital, Basel, Switzerland
Healthy Volunteer
A Study to Compare Blood Levels of Different Dosage Formulations of the Study Medicine That Is a CGRP Receptor Antagonist in Healthy Adults
The purpose of this study is to assess the bioequivalence (medicines that may have different names or be made in different ways, but have the same effect on the body) of different formulations of a CGRP receptor antagonist in…
- Trial name
- NCT07261371
- Testing
- Test formulation (Treatment A), Reference formulation (Treatment B), Test formulation (Treatment C)
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obese Adults
A Phase 1 Study of VK3019 in Overweight and Obese Adults Without Comorbidities
This is a Phase 1, randomized, double-blind, placebo-controlled single ascending dose (SAD) study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of VK3019 in overweight and obese adults without…
- Trial name
- NCT07846033
- Testing
- SC VK3019
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Viking Therapeutics, Inc.
Generalized Chronic Periodontitis, Osteoporosis
A Study to Assess the Disturbances in Calcitonin Gene in Patients With Gum Disease and Osteoporosis
Osteoporosis and Periodontitis are multifactorial diseases which share common risk factors.The aim of the present study is to ellucidate polymorphisms in Calcitonin receptor gene? in patients with Osteoporosis and Periodontitis.
- Trial name
- CTROP (NCT02273128)
- Testing
- CTR Gene
- Where
- India
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre
Migraine, Migraine Without Aura
The Effect of Anti-calcitonin Gene-related Peptide (CGRP) Receptor Antibodies on the Headache Inducing Properties of CGRP and Cilostazol in Migraine Patients
A randomized, double-blind, placebo-controlled, parallel study to investigate the effect of erenumab in calcitonin-gene related peptide and cilostazol experimental models of migraine in humans.
- Conditions
- Migraine, Migraine Without Aura, Migraine With Aura
- Trial name
- NCT04452929
- Testing
- Erenumab, Calcitonin gene-related peptide, Cilostazol
- Where
- Denmark
- Volunteers
- 72 people
- Sponsor
- Danish Headache Center
Migraine
Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine
This study used a single-cohort, 2-treatment arm, parallel-group randomized, double-blind, double-dummy design in adult patients with episodic migraine and chronic migraine, who had to be either naïve or not suitable for or could…
- Trial name
- HER-MES (NCT03828539)
- Testing
- Erenumab, Topiramate
- Where
- 79 sites in Germany
- Volunteers
- 777 people
- Sponsor
- Novartis Pharmaceuticals
Migraine
To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients
Phase I, Randomized, Parallel-group, Double-Blind, Placebo-Controlled, Single Dose Study to Evaluate the Blockade of CGRP Receptor by AMG 334 in Preventing PACAP-38 Induced Migraine-like Attacks in Migraine Patients.
- Trial name
- NCT02542605
- Testing
- Erenumab, PACAP-38 Challenge Agent
- Where
- 3 sites in United States, Belgium and 1 more
- Volunteers
- 35 people
- Sponsor
- Amgen
Angina Pectoris, Coronary Heart Disease
A Study to Assess the Safety, Tolerability, and Effects of MK-0974 (Telcagepant) on Exercise Tolerance in Patients With Stable Angina (MK-0974-014)
This study will assess the safety of telcagepant in coronary artery disease (CAD) participants with stable angina during exercise treadmill testing and evaluate whether calcitonin gene-related peptide (CGRP) receptor antagonism…
- Conditions
- Angina Pectoris, Coronary Heart Disease, Calcitonin Gene-related Peptide Receptor
- Trial name
- NCT01294709
- Testing
- telcagepant
- Volunteers
- 64 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine, Migraine Disorders
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
This is a 128-week open-label study to assess the long-term safety and tolerabilty of the monoclonal antibody erenumab in migraine patients.
- Conditions
- Migraine, Migraine Disorders, Migraine Headache
- Trial name
- APOLLON (NCT04084314)
- Testing
- Erenumab
- Where
- 75 sites in Germany
- Volunteers
- 701 people
- Sponsor
- Novartis Pharmaceuticals
Thyroid Cancer, Medullary
177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer
The purpose of this study is to determine the use of 177Lu-PP-F11N for imaging and therapy of patients with advanced medullary thyroid carcinoma (MTC). 177Lu-PP-F11N is a gastrin analogon, binding to cholecystokinin-2 receptors.
- Trial name
- NCT03647657
- Testing
- 177Lu-PP-F11N, Sacuitril
- Where
- Switzerland
- Volunteers
- 8 people
- Sponsor
- University Hospital, Basel, Switzerland
Migraine
Positron Emission Tomography (PET) Study of Brain Calcitonin Gene-Related Peptide (CGRP) Receptor Occupancy After Telcagepant Administration (MK-0974-067)
The purpose of this study is to determine the receptor occupancy (RO) associated with telcagepant (MK-0974) administration based on displacement of [11C]MK-4232 from the CGRP receptors in the brain using PET.
- Trial name
- NCT01315847
- Testing
- telcagepant, [11C]MK-4232
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Migraine
A Study to Compare the Blood Levels of Two Dosage Formulations of the Study Medicine in Healthy Adults
The purpose of this study is to assess the bioequivalence of an alternative ODT formulation (ODT2) versus the approved ODT formulation of a CGRP receptor antagonist in healthy adult participants under fasting conditions.
- Trial name
- NCT07594769
- Testing
- ODT2 Test formulation, ODT Reference formulation
- Where
- Belgium
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Pfizer
Migraine Disorders, Brain, Healthy Adult Participants
Effect of Atogepant on the Vestibulo-Ocular Reflex in Healthy Adults and Adults With Migraine
Researchers want to find out how a substance in the body called CGRP affects balance. CGRP (calcitonin gene-related peptide) is a small protein involved in migraine. Several approved migraine medicines work by blocking it.
- Conditions
- Migraine Disorders, Brain, Healthy Adult Participants, Vestibulo-Ocular Reflex
- Trial name
- VOR-GRIP (NCT07826910)
- Testing
- Atogepant 60 mg
- Where
- Switzerland
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Konrad Peter Weber
Posttraumatic Headache, Mild Traumatic Brain Injury
Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI
This study aims to assess the effect and safety of erenumab compared to placebo for the treatment of acute posttraumatic headache (PTH) in military service members and civilians with mild traumatic brain injury (mTBI).
- Trial name
- NCT05049057
- Testing
- Erenumab 140 Mg/mL Subcutaneous Solution
- Where
- 4 sites in United States
- Volunteers
- 404 people
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Temporomandibular Disorders
Erenumab-aooe for Temporomandibular Disorders Management: TMD Cgrp Antibody RElief (TMD CARE)
Evaluate erenumab- aooe efficacy as a therapeutic approach, for the management of painful chronic temporomandibular disorders (TMD).
- Trial name
- TMD CARE (NCT05162027)
- Testing
- Erenumab-Aooe 70 MG in 1 mL Prefilled Syringe
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Maryland, Baltimore